NIH Trial Reduces New HIV Infections by 70% in Rural Kenya and Uganda

A landmark clinical trial funded by the U.S. National Institutes of Health has achieved what many thought impossible in the fight against HIV: a 70% reduction in new infections across rural communities in Kenya and Uganda. The study, published in February 2026, used an integrated community health approach that connected HIV testing directly to treatment and prevention services in areas where healthcare infrastructure is minimal and distances to clinics can be vast. Rather than waiting for people to come to hospitals, the programme brought services to them. Community health workers conducted door-to-door testing, immediately linked those who tested positive to antiretroviral therapy, and provided pre-exposure prophylaxis (PrEP) to those at highest risk. The results were striking. In communities receiving the intervention, new HIV infections dropped by 70% compared to control communities receiving standard care. Viral suppression rates — meaning the virus was reduced to undetectable and untransmittable levels — also increased dramatically. 'This demonstrates that with the right strategy, we can dramatically reduce HIV transmission even in the most resource-limited settings,' said researchers involved in the trial. The approach addressed several barriers that have historically hampered HIV prevention in rural Africa: stigma around testing, long travel distances to clinics, and gaps between diagnosis and treatment initiation. By embedding services within the community itself, the programme removed these obstacles. Particularly notable was the programme's success with young women aged 15-24, who bear a disproportionate burden of new HIV infections in sub-Saharan Africa. The community-based approach reached this demographic far more effectively than facility-based programmes. Globally, approximately 39 million people live with HIV, and 1.3 million new infections still occur each year. Sub-Saharan Africa accounts for roughly two-thirds of all people living with HIV worldwide. The trial's success has prompted calls to scale the model across other high-burden regions. Health officials noted that the approach could be adapted for other infectious diseases facing similar barriers to care. After four decades of fighting HIV, this trial offers powerful proof: the end of the epidemic isn't just a slogan — it's achievable. 🌍